Kudos to Pfizer(NYSE:PFE) for its decision to acquire Trillium Therapeutics(NASDAQ:TRIL). The small biotech’s cancer pipeline is a great fit for Pfizer. Trillium’s candidates could begin contributing to Pfizer’s growth in the second half of the decade,…

Click here to view the original article.